Multicenter trial of olmesartan. Main results

Abstract


Development and introduction into practice of medicines reducing activity of the renin-angiotensin-aldosteron system the key element of which is angiotensin II (ATII) resulted in a significant improvement of efficacy of cardiovascular diseases treatment. Angiotensin converting enzyme (ACE) inhibitors and ATII receptor blockers (BRA II) effectively reduce arterial pressure, have a nephroprotective action in patients with diabetes mellitus, inhibit development of left ventricular hypertrophy. Unlike ACE inhibitors, BRA II do not exhibit the phenomenon of ATII concentration escape, they completely depress ATII interaction with AT1-receptors while AT2-receptors keep their ability to interact with this hormone. High probability of target arterial pressure achievement in the treatment with BRA II encourage higher compliance of the patients. The review of multicenter trials performed in 2007-2010 concerns a new BRA II representative - olmesartan medoxomil (OM). The trials run in two directions: hypotensive activity of OM and vaso- and other organ-protective OM properties.

About the authors

Fail' Taipovich Ageev

Email: ageev@cardio.ru

Ol'ga Nikolaevna Svirida

Email: olgasvirida@yandex.ru

F T Ageev

A.L. Myasnikov Research Institute of Cardiology, Cardiological Research Center, Moscow

A.L. Myasnikov Research Institute of Cardiology, Cardiological Research Center, Moscow

O N Svirida

A.L. Myasnikov Research Institute of Cardiology, Cardiological Research Center, Moscow

A.L. Myasnikov Research Institute of Cardiology, Cardiological Research Center, Moscow

References

  1. Miura S., Kiya Y., Kanazawa T. et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol. Endocrinol. 2008; 22(1): 139-146.
  2. Zannad F., Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam. Clin. Pharmacol. 2007; 21(2): 181-190.
  3. Izzo J. L. Jr., Neutel J. M., Silfani T. et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J. Clin. Hypertens. (Greenwich) 2007; 9(1): 36-44.
  4. Izzo J. L. Jr., Neutel J. M., Silfani T. et al. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J. Clin. Hypertens. (Greenwich) 2007; 9(1): 45-48.
  5. Rump L. C., Girerd X., Sellin L., Stegbauer J. Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. J. Hum. Hypertens. advance online publication. 25 November 2010; doi: 10.1038/jhh.2010.105.
  6. Fogari R., Taddei S., Holm-Bentzen M. et al. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Clin. Drug Invest. 2010; 30(9): 581-597.
  7. Ong K. L., Cheung B. M., Man Y. B. et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49(1): 69-75.
  8. Kassai B., Boissel J. P., Cucherat M. et al. Treatment of high blood pressure and gain in event-free life expectancy. Vasc. Hlth Risk Manag. 2005; 1(2): 163-169.
  9. Turnbull F., Neal B., Ninomiya T. et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br. Med. J. 2008; 336(7653): 1121-1123.
  10. Mallion J. M., Heagerty A., Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J. Hypertens. 2007; 25(10): 2168-2177.
  11. Saito I., Kushiro T., Hirata K. et al. The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan. J. Clin. Hypertens. (Greenwich) 2008; 10(4): 272-279.
  12. Cushman W. C., Ford C. E., Cutler J. A. et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J. Clin. Hypertens. (Greenwich) 2002; 4(6): 393-404.
  13. Hansson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351(9118): 1755-1762.
  14. Neutel J. M., Gilderman L. I. Hypertension control in the elderly. J. Clin. Hypertens. (Greenwich) 2008; 10(Supp1. 1): 33-39.
  15. Stamler J., Vaccaro O., Neaton J. D., Wentworth D. For the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
  16. Haffner M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1999; 339: 220-234.
  17. Curb J. D., Pressel S. L., Cutrel J. A. et al. Effect of diureticbased antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. J. A. M. A. 1996, 276: 1886-1892.
  18. Tuomilehto J., Rastenyte D., Birkenhager W. H. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Eng. J. Med. 1999; 340(9): 677-684.
  19. Estasio R. O., Jeffers B. W., Hiatt W. R. et al. The effect of nisoldipine as compared with noninsulindependent diabetes and hypertension. N. Engl. J. Med. 1998; 338: 645-652.
  20. Tatti P., Pahor M., Byington R. B. et al. Outcjme results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FASeT) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
  21. Hanson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
  22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br. Med. J. 1998; 317: 703-713.
  23. Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М.: Универсум Паблишинг: 2000.
  24. Guidelines Subcommitte. 1999 World Health Organization International Society of Hypertension guidelines for the management of hypertension. J. Hypertens. 1999; 17(2): 151-183.
  25. Neutel J. M., Kereiakes D. J. BENIFICIARY Investigators. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am. J. Cardiovasc. Drugs. 2010; 10(5): 289-303.
  26. Neutel J. M., Kereiakes D. J. BENIFICIARY Investigators. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study. Am. J. Cardiovasc. Drugs 2010; 10(5): 289-303.
  27. Mallion J. M. The l5th European meeting on hypertension during the symposia on "The evolution of angiotensin reseptor blokade: more patients, better control, vascular benefits" at Milan (Italy) June 17, 2005, J. Hypertens. Suppl. 2005 Jun; 23(2): 3-416.
  28. Volpe M., Brommer P., Haag U., Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Invest 2009; 29(1): 11-25.
  29. Daiichi Sankyo; ClinicalTrials.gov number, NCT00923091.
  30. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
  31. Pearson T. A., Mensah G. A., Alexander R. W. et al. for the Center for Disease Control and Prevention and American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
  32. Espinola-Klein C., Rupprecht H. J., Blankenberg S. et al. for the AtheroGene Investigators. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105: 15-21.
  33. Magyar M. T., Szikszai Z., Balla J. et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 2003; 34: 58-63.
  34. Saito M., Ishimitsu T., Minami J. et al. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167: 73-79.
  35. Sesso H. D., Buring J. E., Rifai N. et al. C-reactive protein and the risk of developing hypertension. J. A. M. A. 2003; 290: 2945-2951.
  36. Blake G. J., Rifai N., Buring J. E. et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
  37. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999; 340: 448-454.
  38. Ridker P. M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
  39. Yeh E. T., Willerson J. T. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003; 107; 370-371.
  40. Ridker P. M., Rifai N., Rose L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 2002; 347: 1557-1565.
  41. Ridker P. M., Rifai N., Pfeffer M. A. et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230-235.
  42. Albert M. A., Danielson E., Rifai N. et al. for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation CRP Evaluation (PRINCE). J. A. M. A. 2001; 286: 64-70.
  43. Penge J. K., Hernandez T. L., Weil K. M. et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106: 1447-1452.
  44. Brasier A. R., Recinos A., Eledrisi M. S. Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1257-1266.
  45. Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110(9): 1103-1107.
  46. Stumpe K. Q., Agabiti-Rosei E., Zielinski T. et al. MORE study investigators. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther. Adv. Cardiovasc. Dis. 2007; 1(2): 97-106.
  47. Gassanov N., Brandt M. C., Michels G. et al. Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation. Cell Calcium 2006; 39(2): 175-186.
  48. Mogensen C. E. Diabetic renal disease in patients with type 2 diabetes mellitus: new strategies for prevention and treatment. Treat. Endocrinol. 2002; 1(1): 3-11.
  49. Brenner B. M., Cooper M. E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. RENAAL Study Investigators. N. Engl. J. Med. 2001; 345(12): 861-869.
  50. Hermann H., Sadayoshi I., Joseph L. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2011; 364: 907-917.

Statistics

Views

Abstract - 65

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies